| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cb73270990038a2f07f8e78b51ba4bc3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3fde830b0591701764ede40985667c08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cd05e5b72804379b07f4a26cd941a6a8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d95949163ddc9c14e1c1cd81c809eaf2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8bf0ceab440a28b91d70922a4623b1ac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_68c5298c58907d386a2c1a462118cb70 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-522 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-35 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-20 |
| filingDate |
2008-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5f3cf05109e044597e921778b74b2b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b72caf2659615b1b7049badee78e6410
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12b5933f1f5408b10c5e8d346e021fd2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_876623182e911a7bd73afcc40afa440f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9dd880c136f857e38a9e357caa3fe500 |
| publicationDate |
2009-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2009064825-A2 |
| titleOfInvention |
Generation of new bcg vaccine strains protecting against the establishment of latent mycobacterium tuberculosis infection and reactivation from the latent or persistent state |
| abstract |
A vaccine for treating or preventing the establishment of latent tuberculosis infections is provided. The vaccine comprises a recombinant mycobacterium that overexpresses the transcription factor DosR, at a level sufficient to induce production of the dosR regulon genes or proteins. A host to whom the vaccine is administered mounts an immune response to the dosR regulon proteins and is thus protected from the establishment, persistence or reactivation of latent tuberculosis. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9211529-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015104380-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10765731-B2 |
| priorityDate |
2007-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |